Basel, November 28, 2007 - Tasigna (nilotinib) has received European Union approval as a new anti-cancer therapy for patients with a life-threatening form of leukemia who are resistant or intolerant to prior treatment including Glivec (imatinib)[*].
Read More...
[Source: Yahoo! News Search Results for liver disease help]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment